Dr Dmitry Zamoryakhin, MD, MBA, MFPM

Dmitry has led programs utilizing diverse therapeutic modalities, such as lentiviral vectors, mRNA platforms, CAR-T therapies, antibody-drug conjugates (ADCs), and drug-device combinations. He has advanced therapies targeting complex and hard-to-treat conditions, including glioblastoma (GBM), diffuse midline glioma (DMG), bladder cancer, hematologic malignancies, Parkinson’s disease, hereditary ocular disorders, and sickle cell disease, among others.

Key accomplishments include the development of convection-enhanced drug delivery (CEO) approaches for brain tumors, leading first-in-human trials for targeted therapies in GBM and DMG, and the successful design of clinical strategies for CAR-T therapies in hematologic oncology.

Beyond oncology and rare diseases, Dmitry has extensive experience in neurological and genetic conditions, having led the early clinical development of gene therapies for Parkinson’s disease and hereditary ocular conditions. His expertise also includes regulatory strategy and collaboration with global health authorities to secure trial approvals and align clinical development with evolving regulatory frameworks.

With a strong focus on precision medicine and tailored therapeutic approaches, Dmitry works with biotechnology companies to navigate the complexities of drug development. His goal is to bring groundbreaking therapies to patients faster by leveraging strategic planning, clinical insight, and regulatory expertise.